Publications by authors named "Izanne Roos"

Claim this Profile
M
Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis.
Yi Chao Foong, Daniel Merlo, Melissa Gresle, Katherine Buzzard, Dana Horakova, Izanne Roos

J Neurol Neurosurg Psychiatry· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing reactivation of multiple sclerosis during treatment with natalizumab.
Nathaniel Lizak, Sifat Sharmin, Dana Horáková, Eva Kubala Havrdova, Sara Eichau, Izanne Roos

Mult Scler· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years.
Jodie I Roberts, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Serkan Ozakbas, Izanne Roos

J Neurol Neurosurg Psychiatry· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive impairment in hematology patients planned for chimeric antigen receptor T-cell therapy.
Valeriya Kuznetsova, Hannah Rosenfeld, Carmela Sales, Sam van der Linde, Izanne Roos

Expert Rev Hematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease course after pregnancy in women with progressive multiple sclerosis symptoms.
Jessica Shipley, Heidi N Beadnall, Paul G Sanfilippo, Dana Horakova, Cavit Boz, Izanne Roos

Mult Scler· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of natalizumab in secondary progressive multiple sclerosis: analysis of two phase III trials.
Winston Dzau, Izanne Roos, Tomas Kalincik

J Neurol Neurosurg Psychiatry· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistent progression independent of relapse activity in multiple sclerosis.
Chao Zhu, Zhen Zhou, Tomas Kalincik, Izanne Roos, Katherine Buzzard

Brain Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability.
Jessica Shipley, Heidi N Beadnall, Paul G Sanfilippo, Wei Zhen Yeh, Dana Horakova, Izanne Roos

JAMA Netw Open· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024).
Vilija G Jokubaitis, Raed Alroughani, Ayse Altintas, Sara Eichau, Stella Hughes, Izanne Roos

Mult Scler· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis.
Tomas Kalincik, Sifat Sharmin, Izanne Roos, Mark S Freedman, Harold Atkins

Brain· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data.
Ashkan Pirmani, Edward De Brouwer, Ádám Arany, Martijn Oldenhof, Antoine Passemiers, Izanne Roos

NPJ Digit Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.
Jannis Müller, Sifat Sharmin, Johannes Lorscheider, Serkan Ozakbas, Rana Karabudak, Izanne Roos

JAMA Neurol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.
Johannes Lorscheider, Alessio Signori, Suvitha Subramaniam, Pascal Benkert, Sandra Vukusic, Izanne Roos

J Neurol Neurosurg Psychiatry· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Explainable time-to-progression predictions in multiple sclerosis.
Robbe D'hondt, Klest Dedja, Sofie Aerts, Bart Van Wijmeersch, Tomas Kalincik, Izanne Roos

Comput Methods Programs Biomed· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 1.
Jessica Shipley, James Beharry, Wei Yeh, Nabil Seery, Yi Chao Foong, Izanne Roos

Med J Aust· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 2.
Jessica Shipley, James Beharry, Wei Yeh, Nabil Seery, Yi Chao Foong, Izanne Roos

Med J Aust· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study.
Jannis Müller, Sifat Sharmin, Johannes Lorscheider, Dana Horakova, Eva Kubala Havrdova, Izanne Roos

CNS Drugs· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study.
Pakeeran Siriratnam, Saif Huda, Anneke Van der Walt, Paul Sanfilippo, Sifat Sharmin, Izanne Roos

J Neurol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD.
Pakeeran Siriratnam, Saif Huda, Anneke Van Der Walt, Paul G Sanfilippo, Sifat Sharmin, Izanne Roos

Neurology· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years.
Michelle A Neller, George R Ambalathingal, Nada Hamad, Joe Sasadeusz, Rebecca Pearson, Izanne Roos

Nat Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.
Anoushka P Lal, Yi Chao Foong, Paul G Sanfilippo, Tim Spelman, Louise Rath, Izanne Roos

J Neurol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
Izanne Roos, Sifat Sharmin, Charles Malpas, Serkan Ozakbas, Jeannette Lechner-Scott

Mult Scler· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuropsychological outcomes of patients with haematological malignancies undergoing chimeric antigen receptor T-cell therapy: protocol for a prospective study.
Valeriya Kuznetsova, Harsh Oza, Hannah Rosenfeld, Carmela Sales, Samantha van der Linde, Izanne Roos

BMJ Neurol Open· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries.
Sifat Sharmin, Izanne Roos, Charles B Malpas, Pietro Iaffaldano, Marta Simone

Lancet Child Adolesc Health· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis.
Jannis Müller, Izanne Roos, Tomas Kalincik, Johannes Lorscheider, Edoardo Galli

Brain Behav· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis